


DB1113

| | |
|---------------------------|--|
| Cat. No.: | HY-148061 |
| CAS No.: | 2769753-53-7 |
| Molecular Formula: | C ₅₉ H ₆₈ F ₃ N ₁₃ O ₆ S |
| Molecular Weight: | 1144.31 |
| Target: | Bcr-Abl; CDK; Salt-inducible Kinase (SIK); Cyclin G-associated Kinase (GAK); MAP4K; MAPKAPK2 (MK2); PROTACs; Ferroptosis; ULK; LIM Kinase (LIMK) |
| Pathway: | Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; PROTAC; Apoptosis; Autophagy |
| Storage: | Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 60 mg/mL (52.43 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent | | 1 mg | 5 mg | 10 mg |
|---------------------------|---------------|------|-----------|-----------|-----------|
| | Concentration | Mass | | | |
| | 1 mM | | 0.8739 mL | 4.3694 mL | 8.7389 mL |
| | 5 mM | | 0.1748 mL | 0.8739 mL | 1.7478 mL |
| | 10 mM | | 0.0874 mL | 0.4369 mL | 0.8739 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity^[1].

IC₅₀ & Target

| | | | |
|------|--------|--------|------------|
| CDK4 | CDK11B | MAP4K2 | SIK2 |
| SIK3 | MAP4K5 | HPK1 | GLK/MAP4K3 |
| ULK1 | LIMK1 | | |

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA